🔗 Share this article Patients Stopping Weight-Loss Medications Regain Weight at a Quadrupled Rate Compared to People Using Diet and Exercise Weight management involves ongoing approaches. New research indicates that patients who discontinue popular weight-loss injections like semaglutide or tirzepatide may regain lost weight far faster than those who halt traditional diet and exercise programs. Published data in a major health publication points out that while obese individuals often shed substantial amounts of their total mass while on the medication, the weight returns at an average rate of nearly a kilo each month once they quit. "Users using such drugs need to be cognizant of the danger of quick rebound weight gain when the medication concludes," stated researcher Dr. Susan Jebb. This pace of recovery suggests a reversion to original weight within about 18 months. Weighing Approaches The study, which looked at dozens of trials involving thousands of patients, compared the outcomes of these new drugs with older methods. Researchers emphasize that people who lose weight through diet and exercise usually see a more gradual creep back—approximately 0.1 kg a month—post-intervention. Explaining the Quick Rebound Doctors believe the way of the drugs explains the heightened weight return. These medications mimic a natural hormone called glucagon-like peptide-1, which moderates hunger. "Artificially providing GLP-1 levels several times higher than the body's typical production may cause the system to produce less of its own natural hormone, and may also diminish responsiveness to its actions," explained Dr. Adam Collins, a dietetics expert. "Stopping of this GLP-1 'fix' leads to hunger is unsuppressed, making excessive eating far more likely." A Lifelong Condition? Medical guidelines advise the injections for people with weight-linked health risks, accompanied by prescribed diet and exercise modifications. Professionals argue that, considering the significant potential of relapse, the therapy might need to be ongoing. This opinion is supported by pharmaceutical companies, who note that the findings "highlight the long-term character of obesity," akin to managing diseases like high blood pressure. User Experiences People who have come off the jabs report a intense resurgence of hunger. "It was like a switch that goes on and you become extremely hungry," described an individual. The struggle is worsened if individuals have not developed sustainable lifestyle or habit changes during treatment. Growing Interest Survey data show that a significant number of adults in the UK have used these injections in the last 12 months, with demand continuing to grow. Adoption is more common among females than males. The 40s and 50s demographic shows the highest level of interest. A large proportion obtain the medications through private prescriptions rather than public health services. Ultimately, experts stress that while the jabs are powerful agents for shedding pounds, they are not a standalone solution and lasting health benefits likely depends on combined behavioural changes.
Weight management involves ongoing approaches. New research indicates that patients who discontinue popular weight-loss injections like semaglutide or tirzepatide may regain lost weight far faster than those who halt traditional diet and exercise programs. Published data in a major health publication points out that while obese individuals often shed substantial amounts of their total mass while on the medication, the weight returns at an average rate of nearly a kilo each month once they quit. "Users using such drugs need to be cognizant of the danger of quick rebound weight gain when the medication concludes," stated researcher Dr. Susan Jebb. This pace of recovery suggests a reversion to original weight within about 18 months. Weighing Approaches The study, which looked at dozens of trials involving thousands of patients, compared the outcomes of these new drugs with older methods. Researchers emphasize that people who lose weight through diet and exercise usually see a more gradual creep back—approximately 0.1 kg a month—post-intervention. Explaining the Quick Rebound Doctors believe the way of the drugs explains the heightened weight return. These medications mimic a natural hormone called glucagon-like peptide-1, which moderates hunger. "Artificially providing GLP-1 levels several times higher than the body's typical production may cause the system to produce less of its own natural hormone, and may also diminish responsiveness to its actions," explained Dr. Adam Collins, a dietetics expert. "Stopping of this GLP-1 'fix' leads to hunger is unsuppressed, making excessive eating far more likely." A Lifelong Condition? Medical guidelines advise the injections for people with weight-linked health risks, accompanied by prescribed diet and exercise modifications. Professionals argue that, considering the significant potential of relapse, the therapy might need to be ongoing. This opinion is supported by pharmaceutical companies, who note that the findings "highlight the long-term character of obesity," akin to managing diseases like high blood pressure. User Experiences People who have come off the jabs report a intense resurgence of hunger. "It was like a switch that goes on and you become extremely hungry," described an individual. The struggle is worsened if individuals have not developed sustainable lifestyle or habit changes during treatment. Growing Interest Survey data show that a significant number of adults in the UK have used these injections in the last 12 months, with demand continuing to grow. Adoption is more common among females than males. The 40s and 50s demographic shows the highest level of interest. A large proportion obtain the medications through private prescriptions rather than public health services. Ultimately, experts stress that while the jabs are powerful agents for shedding pounds, they are not a standalone solution and lasting health benefits likely depends on combined behavioural changes.